Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01082926
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:35:54.166596+00:00
Published At
2015-06-08T00:00:00+00:00
Record Updated At
2015-06-08
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Anaplastic Astrocytoma", "Anaplastic Ependymoma", "Anaplastic Meningioma", "Anaplastic Oligodendroglioma", "Brain Stem Glioma", "Ependymoblastoma", "Giant Cell Glioblastoma", "Glioblastoma", "Gliosarcoma", "Grade III Meningioma", "Meningeal Hemangiopericytoma", "Mixed Glioma", "Pineal Gland Astrocytoma", "Brain Tumor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2015-06-08"
protocolSection.identificationModule.nctId
"NCT01082926"
protocolSection.identificationModule.officialTitle
"Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Anaplastic Astrocytoma (protocolSection.conditionsModule.conditions)
  • Anaplastic Ependymoma (protocolSection.conditionsModule.conditions)
  • Anaplastic Meningioma (protocolSection.conditionsModule.conditions)
  • Anaplastic Oligodendroglioma (protocolSection.conditionsModule.conditions)
  • Brain Stem Glioma (protocolSection.conditionsModule.conditions)
  • Ependymoblastoma (protocolSection.conditionsModule.conditions)
  • Giant Cell Glioblastoma (protocolSection.conditionsModule.conditions)
  • Glioblastoma (protocolSection.conditionsModule.conditions)
  • Gliosarcoma (protocolSection.conditionsModule.conditions)
  • Grade III Meningioma (protocolSection.conditionsModule.conditions)
  • Meningeal Hemangiopericytoma (protocolSection.conditionsModule.conditions)
  • Mixed Glioma (protocolSection.conditionsModule.conditions)
  • Pineal Gland Astrocytoma (protocolSection.conditionsModule.conditions)
  • Brain Tumor (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.